Vanguard Group
CNTX icon

Vanguard Group’s Context Therapeutics CNTX Stock Holding History

Vanguard Group’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$5.57M Buy
3,785,909
+290,878
+8% +$340K ﹤0.01% 3212
2025
Q3 		$3.39M Buy
3,495,031
+134,449
+4% +$109K ﹤0.01% 3407
2025
Q2 		$2.2M Buy
3,360,582
+107,115
+3% +$77K ﹤0.01% 3504
2025
Q1 		$1.99M Sell
3,253,467
-1,996
-0.1% -$1.74K ﹤0.01% 3491
2024
Q4 		$3.42M Sell
3,255,463
-489,498
-13% -$847K ﹤0.01% 3403
2024
Q3 		$7.34M Sell
3,744,961
-757,237
-17% -$1.68M ﹤0.01% 3108
2024
Q2 		$9.03M Buy
4,502,198
+3,903,895
+652% +$6.73M ﹤0.01% 2987
2024
Q1 		$826K Buy
598,303
+2,291
+0.4% +$2.58K ﹤0.01% 3875
2023
Q4 		$673K Buy
596,012
+2,521
+0.4% +$2.71K ﹤0.01% 3947
2023
Q3 		$896K Buy
593,491
+18,791
+3% +$21.3K ﹤0.01% 3879
2023
Q2 		$920K Buy
574,700
+1,300
+0.2% +$1.11K ﹤0.01% 3932
2023
Q1 		$322K Sell
573,400
-67,463
-11% -$51K ﹤0.01% 4230
2022
Q4 		$418K Buy
640,863
+164
+0% +$177 ﹤0.01% 4150
2022
Q3 		$711K Buy
640,699
+11,720
+2% +$21.1K ﹤0.01% 4106
2022
Q2 		$1.33M Buy
628,979
+392,700
+166% +$736K ﹤0.01% 3989
2022
Q1 		$513K Buy
236,279
+21,600
+10% +$45.4K ﹤0.01% 4392
2021
Q4 		$571K Buy
+214,679
New +$1.07M ﹤0.01% 4408

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Vanguard Group's CNTX Position: Q4 2025 in Review

Vanguard Group increased its Context Therapeutics (CNTX) stake by 8.3% in Q4 2025, buying an estimated $340K and bringing the position to 3,785,909 shares worth $5.57M. The position accounts for ﹤0.01% of the portfolio, ranked #3212.

Vanguard Group first reported a position in CNTX in Q4 2021 and has held it in 17 quarters since. The position peaked at $9.03M in Q2 2024. 42 funds tracked by Wall St. Rank hold CNTX as of Q4 2025.

  • Vanguard Group held 3,785,909 shares of Context Therapeutics worth $5.57M as of Q4 2025.
  • Vanguard Group bought 290,878 Context Therapeutics shares in Q4 2025, an estimated $340K.
  • Context Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3212 holding.
  • Vanguard Group first reported a position in Context Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • Vanguard Group's Context Therapeutics position peaked at $9.03M in Q2 2024.
  • 42 funds tracked by Wall St. Rank held Context Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.